alur stock Allurion Technologies (ALUR) Overview

This article explains alur stock (ALUR), the NYSE-listed equity of Allurion Technologies, Inc., covering company background, products (swallowable intragastric balloon and digital care suite), clin...

2024-07-08 04:32:00

By Ravi Clark

Article rating

4.6

106 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Allurion Technologies, Inc. (ALUR)

alur stock refers to the publicly traded equity of Allurion Technologies, Inc. (NYSE: ALUR). This guide explains what alur stock represents, the company’s core business in non-surgical obesity treatments and digital health, key milestones, financial and market metrics, regulatory and clinical context, and practical points investors and researchers often check before following the ticker. Read on to get a structured, factual view of Allurion and the considerations frequently cited by market-data platforms and health-industry coverage.

Company overview

Allurion Technologies, Inc. develops medical-device and digital-health solutions focused on non-surgical weight loss and obesity-care pathways. The company’s core offering centers on a swallowable intragastric balloon (often referred to as the Allurion Balloon) combined with a digital care platform and connected devices (scale and trackers) to support behavior change and remote monitoring.

Headquarters: United States (company filings and investor pages list a U.S. corporate presence).
Business model: device sales and provider partnerships, bundled patient programs, and recurring digital-care services to complement device procedures.
Core products: Allurion Balloon (swallowable intragastric balloon), Allurion Virtual Care Suite (mobile apps, remote monitoring, care pathways), connected scales and activity trackers used for program tracking.
Employees: a growth-stage medtech headcount (company disclosures and market pages indicate a workforce consistent with early commercial-stage medical-device firms).

As a reminder, alur stock denotes the company shares traded on the NYSE under the ticker ALUR; the equity is distinct from crypto tokens or other uses of the string "alur."

History and corporate timeline

Formation and early development

Allurion’s origins trace to R&D and clinical development of a non-surgical intragastric balloon designed to be swallowed as a capsule, then inflated in the stomach without endoscopic placement, with planned natural deflation and passage after a set period. Early work emphasized a low-resource procedural profile to broaden access beyond surgical centers, and the company paired the device with digital tools for remote monitoring and patient engagement.

Founders and early teams combined expertise in medical-device design, endocrinology/obesity care, and digital-health product engineering. Early clinical and feasibility trials established safety and weight-loss signals that supported subsequent commercial launches in select markets.

Public listing and financings

alur stock became available on the NYSE when Allurion completed its public-market transaction and listing (company filings and exchange notices provide the specific listing date and transaction details). Since listing, Allurion engaged in capital markets activity typical of growth-stage medtechs, including equity financings and selective debt or placement transactions intended to support commercialization and clinical programs. As of recent filings, the company has undertaken financing steps to extend runway and support operational expansion.

As of 2026-01-24, according to public market sources (see References), alur stock is publicly quoted on the NYSE and covered by investor-data platforms reporting price, volume and company filings.

Products and services

Allurion’s product suite combines a physical, single-use medical device with digital services and connected hardware.

Allurion Balloon: a swallowable intragastric balloon that expands after ingestion and remains in place for a defined treatment period before emptying and passing naturally. The design aims to offer a non-surgical alternative to endoscopically placed balloons and to lower procedural resource needs.
Allurion Virtual Care Suite: a digital platform consisting of mobile apps, clinician dashboards and remote monitoring tools designed to track weight, biometrics, activity and patient progress. The platform also supports telehealth follow-ups and personalized behavior-change programs.
Connected devices: scales, activity trackers and related peripherals provided as part of patient programs to feed objective measurements into the virtual care platform.

Products are typically delivered through healthcare-provider partners (clinics, weight-management centers) and sometimes via direct-to-consumer program arrangements where local clinical oversight is coordinated.

Clinical use and procedures

The Allurion Balloon is intended as a non-surgical, temporary intragastric balloon used in supervised weight-loss programs. A typical pathway includes:

Eligibility assessment and informed consent by a clinician.
Swallowing a capsule that expands into a balloon once positioned in the stomach; expansion is usually confirmed by imaging or other clinician checks depending on local protocols.
A defined treatment period (often a few months), during which patients follow a structured diet, behavior program and remote monitoring via the Virtual Care Suite.
Balloon deflation and natural passage, followed by follow-up and maintenance care.

The device is indicated for use under clinician supervision, and programs emphasize multidisciplinary support, nutritional counseling and follow-up to maintain weight loss after balloon passage.

Digital health and AI features

Allurion’s care platform emphasizes remote monitoring, analytics and patient engagement features. The Virtual Care Suite aggregates weight and activity data from connected devices, supports clinician dashboards for progress tracking, and delivers behavior-change modules. Company materials and product descriptions refer to analytics-based personalization and trend detection; some public materials reference algorithmic features to help clinicians identify patients needing intervention.

Research, clinical studies and regulatory status

Allurion has sponsored and supported clinical studies and published peer-reviewed research assessing safety and efficacy of the balloon and associated programs. Clinical literature has reported weight-loss outcomes in line with non-surgical intragastric balloon therapies, with some studies highlighting feasibility of a swallowable device and the value of integrated digital care in supporting adherence.

Regulatory status is jurisdiction-specific: approvals, clearances or registrations vary between countries and regulatory frameworks (e.g., CE marking in Europe, local health-authority listings). In the U.S., regulatory interactions and required submissions are detailed in company filings and regulatory notices. For current trial statuses and any active FDA interactions, check company filings and clinical-trial registries.

Markets and partnerships

Allurion targets markets where device-based, non-surgical weight-loss options have clinical demand, including Europe, the Middle East, Asia and selected U.S. channels where regulatory pathways and reimbursement permit. The company uses a mix of direct provider partnerships, distributor agreements and programmatic rollouts with specialist clinics.

Strategic partners often include obesity clinics, health systems, and providers focusing on metabolic disease management. Market-entry strategies emphasize training for clinicians and integration of the Virtual Care Suite into local care pathways.

Financial profile

Investors following alur stock should note that Allurion is positioned as a commercializing medtech with growth-stage financial characteristics: revenue generation from device and program sales alongside ongoing investments in R&D, regulatory activities and commercial expansion.

Revenue and profitability: Recent annual and quarterly filings show early-stage revenue with ongoing net losses as the company invests in commercialization. Year-over-year revenue trends depend on rollout pace across geographies and adoption by provider partners.
Cash position and liquidity: Public filings disclose cash-on-hand and working capital metrics at reporting dates; financing transactions since listing have been used to extend runway. As of recent reporting windows, the company disclosed a financing and liquidity plan in public filings and investor releases (see References for source links and dates).
Micro-cap profile: alur stock is described by market-data services as a micro-cap or small-cap issuer (market-cap band below larger-cap medtechs), implying higher volatility and market sensitivity to news and financing events.

Historical revenue and profitability

Allurion’s reported revenue history shows early revenue with incremental growth as commercial programs scale. Profitability remains negative in recent periods, consistent with the company’s investments in sales, marketing and R&D to support broader adoption.

Balance sheet and liquidity

Balance-sheet notes in recent filings include cash, short-term assets and any disclosed debt or contractual liabilities. Company statements and investor presentations have described capital-raising activities since listing; check the most recent 10-Q/10-K or equivalent periodic reports for precise figures and recent cash runway disclosures.

Stock information and market performance

Ticker symbol: ALUR (NYSE).
Exchange: New York Stock Exchange (NYSE).
Market-cap band: market-data platforms classify alur stock in the micro-cap segment (public sources report market capitalization in the low hundreds of millions or less depending on share price fluctuations; see References for up-to-date figures).
Trading volume: average daily trading volume for alur stock varies widely; market pages report volumes that can spike on news or financing announcements.
52-week range: financial portals publish the current 52-week high and low; consult market-data pages for the latest range on the trading date of interest.

Price history and volatility

alur stock has shown periods of pronounced volatility typical of micro-cap and clinical-stage medtechs. Price movement is often driven by clinical updates, regulatory news, financing transactions, and broader market sentiment for growth-healthcare names.

As of 2026-01-24, according to Yahoo Finance and NYSE quote pages referenced in market-data summaries, alur stock’s intraday price and 52-week range are available on public quote pages (see References). Traders and long-term observers should expect higher relative volatility versus large-cap equities.

Analyst coverage and sentiment

Coverage of alur stock among sell-side analysts may be limited; investor-sentiment indicators on platforms such as StockTwits and community broker pages show retail engagement and discussion. Market-data platforms collate analyst notes where available; overall sell-side coverage is typically lighter for micro-cap medtechs than for large healthcare names.

Retail sentiment metrics (message volume and social mentions) can be tracked on community-driven sites—these are supplemental signals, not substitutes for company filings or clinical data.

Ownership and short interest

Public filings disclose insider ownership and institutional holdings at reporting cutoffs. For short interest, market-data services publish short-interest metrics and days-to-cover calculations on periodic schedules. alur stock’s ownership profile typically includes company insiders, early investors and selective institutional holders where disclosed; check the latest 13D/13G and institutional-holding reports for up-to-date ownership percentages.

Corporate governance and management

Key executive leadership and board composition are presented in the company’s proxy statements and investor pages. Typical public-company disclosures include CEO and CFO biographies, board-member backgrounds and governance practices (committees, independence assessments). Recent leadership changes or governance actions are reported in press releases and SEC filings; consult the latest filings for precise personnel details and dates.

Regulatory, legal and risk factors

Investors and researchers should examine the risk factors section of Allurion’s public filings for a comprehensive, company-stated list of material risks. Typical areas include:

Regulatory risk: approvals, clearances or compliance issues in key markets.
Clinical and product-safety risk: adverse events or device complications could affect use and adoption.
Reimbursement and access: payor coverage and reimbursement policies that influence adoption by providers.
Financing risk: need for additional capital to fund operations and growth.
Competitive risk: competing therapies and technologies (surgical, device-based, and pharmaceutical options).

Reported litigation or material regulatory interactions are disclosed in company filings and press releases; check the periodic reports for any open legal proceedings or regulatory inquiries.

Recent news and developments

Notable recent items that typically impact alur stock include quarterly earnings releases, clinical-study updates, regulatory clearances or trial initiations, strategic partnerships, and financing announcements. As of 2026-01-24, market-data outlets and company press releases report on the company’s most recent results and corporate actions (see References). For timeline context, check:

Company earnings and investor presentations (quarterly releases).
Press releases about partnerships with clinics or distributors.
Clinical-trial registries and peer-reviewed publications reporting study outcomes.

All public press releases and filings provide the authoritative timeline of events; market-data aggregators summarize these items alongside quote changes.

Investment considerations

This section lists objective factors commonly reviewed by investors and analysts when evaluating alur stock. It is informational, not a recommendation.

Growth drivers: uptake of the Allurion Balloon and expansion of virtual-care partnerships could increase recurring program revenue.
Clinical evidence: positive study outcomes and peer-reviewed publications support adoption; regulatory clearances in new markets can expand addressable opportunity.
Reimbursement: availability of payor coverage for device-procedures and integrated care programs materially affects scaling.
Cash runway: capital requirements for commercial expansion and clinical studies may necessitate further funding rounds; financing terms and timing can influence shareholder dilution and share price volatility.
Competitive environment: competition includes surgical alternatives, other intragastric balloons, pharmaceutical therapies (including GLP-1 receptor agonists and related drugs), and digital therapeutics—each with different efficacy, risk and cost profiles.
Market sentiment and liquidity: as a micro-cap, alur stock typically carries lower liquidity and higher sensitivity to news and small-volume trading.

Competitors and industry context

Allurion competes in the broader obesity-care ecosystem rather than a single direct market. Competitor categories include:

Other intragastric balloons and endoscopic bariatric devices.
Surgical weight-loss procedures performed by bariatric surgeons.
Pharmacological therapies for weight loss (e.g., GLP-1 receptor agonists and other emerging drugs) that have reshaped treatment patterns.
Digital therapeutics and remote-care platforms targeting behavioral weight management.

Allurion’s positioning relies on a combined-device-plus-digital approach aimed at patients seeking non-surgical options and on provider channels that prefer lower-resource procedures.

References and data sources

Primary market-data and reporting sources used by investors and researchers for alur stock include (representative examples):

Yahoo Finance (ALUR) — market quotes, 52-week range, market-cap snapshots.
CNN Markets and other financial-news aggregators — high-level market context and company summaries.
StockTwits and retail-investor platforms — sentiment and community commentary.
Broker/retail platforms (quote pages) that mirror exchange quotes and provide basic company data.
Finviz and StockAnalysis — screening and summarization tools with metrics such as market cap, volume and performance.
NYSE quote page and official exchange disclosures for listing details and official quote data.
Company filings and investor relations materials (SEC filings or equivalent) for audited financials, risk factors and corporate disclosures.

As of 2026-01-24, according to Yahoo Finance and the NYSE quote page, alur stock (ALUR) is listed and publicly traded on the New York Stock Exchange; specific intraday prices, 52-week range and volume figures are available on those pages on the quoted date.